Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Design Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 95 | 1 | 117 | +23 |
| Shares | 34.5M | 5.70K | 38.1M | +3.63M (+10.5%) |
| Value | $259.7M | $42.9K | $357.6M | +$97.9M (+37.7%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (31)
Institutions that held Design Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (8)
Institutions that held Design Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Tang Capital Management LLC | 1,780,975 | $13.4M |
| MPM Oncology Impact Management LP | 555,187 | $4.18M |
| DLD Asset Management, LP | 50,000 | $376.5K |
| HRT Financial LP | 31,903 | $240.0K |
| Sphera Funds Management Ltd. | 21,918 | $165.0K |
| Intech Investment Management LLC | 14,155 | $106.6K |
| Rise Advisors, LLC | 130 | $979 |
| Versant Capital Management, Inc | 71 | $535 |
Not filed for Q4 2025 yet (1)
Institutions that held Design Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 5,702 | $42.9K |